Vertex Pharmaceuticals' Emmens Interview on Telaprevir

Loading player, please wait...

Recommended Videos

  • Info

  • Comments

Sept. 8 (Bloomberg) -- Matthew Emmens, chief executive officer of Vertex Pharmaceuticals Inc., talks with Bloomberg's Julie Hyman about the outlook for the company's experimental hepatitis C treatment, in development with Johnson & Johnson, called telaprevir. A study found that telaprevir worked in patients with hepatitis C who didn’t respond to other treatment. No proven medicines are available for hepatitis C patients who don’t respond to standard care. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change